© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Ferrostatin-1 caught my attention a few years ago thanks to its impact on the study of ferroptosis. Before ferrostatin-1 entered the picture, most labs focused on apoptosis or necrosis when they explored cell death. Our understanding was mechanical—a cell dies this way, or that way, sometimes both. Then researchers in the early 2010s noticed that certain cell deaths did not follow the rules. They saw a regulated process driven by iron-dependent lipid peroxidation. Ferrostatin-1 emerged from careful screening as a molecule that could stop this newly defined cell death in its tracks. This opened new questions about how cells self-destruct, especially in diseases involving oxidative stress.
Today, ferrostatin-1 has a reputation as a niche small molecule with a specific purpose. Its chemical blueprint—a combination of aromatic rings anchored to an amine—offers the right structure to intercept lipid radicals. That unique configuration allows it to intervene where antioxidants like Vitamin E fall short. It comes as an off-white powder that looks unremarkable at first. Still, the granularity and texture tell a story of careful synthesis, often handled in small vials in academic labs. Solubility varies. Dissolving it in DMSO is straightforward, and it blends well with aqueous buffers at low concentrations, suited for cell culture studies.
Ferrostatin-1 stands out for its stability under lab conditions and minimal degradation in standard cell media over short periods. It holds up in the freezer for months, ready for experiments on ferroptosis. Mass spectrometry confirms its integrity batch after batch, a must for consistent research outcomes. The molecule does have its quirks. Exposure to strong acids or prolonged light degrades it. Its moderate molecular weight allows easy handling, yet chemical intuition says: gloves on, no open bottles on the bench.
Synthesizing ferrostatin-1 is not exactly a weekend project in the average university lab, though experts can run it up in-house. The classic prep uses simple aromatic starting materials through condensation and reduction. Adjusting reaction conditions shifts the purity and yield. Some chemists test subtle tweaks—altering side chains, swapping solvent systems—to fine-tune how ferrostatin-1 behaves in cells or animals. Derivatives with bulkier groups can stick around longer in tissues, which expands the toolkit for deeper research. Modifications also support labeling ferrostatin-1 with fluorescent tags or radioactive isotopes, perfect for mechanistic studies.
Other names often crop up—Fer-1 is the shorthand. Literature sometimes references 'ferroptosis inhibitor I' or catalog numbers, especially in big multi-center studies. Its presence in reagent catalogs signals growing demand, but each supplier's labeling reflects the same core structure. This has lowered the risk of confusion and eased collaboration for teams tackling iron-driven cell dysfunction.
Handling ferrostatin-1 is safer than many aldehyde-containing dyes or volatile organic compounds, provided common sense prevails. Proper gloves, a clean workspace, and well-ventilated areas become second nature to anyone used to chemical research. No one wants to risk skin exposure or contamination. Instructions focus on dry storage and quick transfer to solution; leaving ferrostatin-1 out in humid air can sap its punch before an experiment even begins. Waste handling keeps the environment in mind—chemical solvents and any unused powder ought to end up in hazardous waste bottles, never down the drain.
My own work with ferrostatin-1 started in cell biology, but its reach has spread far beyond. Neurons dying in stroke models, kidney cells battling acute failure, or cancer cells resisting chemotherapy—the compound took on a starring role each time. In neuroscience, blocking ferroptosis with ferrostatin-1 preserved neuron health in models of Parkinson’s disease and spinal cord injury. Kidney studies used it to cut down on damage from constricted blood flow, with promising preclinical results. In cancer research, teams use ferrostatin-1 to test if tumors rely on ferroptosis for survival when traditional treatments lose their punch. It challenges researchers to reconsider how cell fate decisions drive disease and recovery.
The attention around ferrostatin-1 has fired up broad research efforts. Chemistry departments build on the original scaffold, trying to push potency or optimize delivery to specific tissues. Industry has taken to screening for similar molecules as potential therapeutics. Big questions are still on the table, like how to fine-tune ferroptosis inhibition in living animals without unintended side effects. Drug makers want to go after neurodegeneration, organ failure, and even rare disorders where standard treatments stall. Funding keeps rolling in because real opportunity lies in understanding iron’s hidden role in disease.
Toxicology labs have tested how ferrostatin-1 acts in model systems. Results show that it behaves as advertised at normal concentrations, quietly protecting cells. At higher doses—far beyond those used in most studies—it can tilt cell metabolism or interfere with key enzyme systems. There’s no evidence for high-level off-target effects in short-term use, but longer experiments in animals call for close monitoring. Researchers warn about staying within tested dose ranges and watching for steps where new derivatives stray from the parent molecule’s profile.
Looking ahead, ferrostatin-1 keeps churning up new ideas. It pushes disease models beyond old boundaries—teaching medical science how iron-driven death spreads or stalls in tissues from brain to kidney. Trials with better delivery systems, combinations with current drugs, and new variations all hint at therapies that could address needs in stroke, trauma, or cancer. The final answers won’t come without steady hands, honest data, and plenty of cross-lab cooperation. Ferrostatin-1 serves as a reminder: real impact often starts with a single compound that turns accepted wisdom on its head.
Researchers have been using Ferrostatin-1, often called Fer-1, as a small molecule to stop a process called ferroptosis. While it doesn’t carry a catchy label like “miracle cure,” this compound has quietly reshaped how labs think about certain diseases, from brain injury to heart disease, diabetes, cancer, and even problems linked to aging.
Not all cell death looks the same. Ferroptosis, for example, happens when iron and certain fats react, causing stress inside cells until they break down. I remember reading about how a single stroke or traumatic brain injury can toss brain cells into chaos, and a domino effect destroys even more tissue. Ferrostatin-1 came onto the scientific scene because researchers wanted a way to slow down this chain reaction.
This isn’t just about cells in a dish. Early work showed that blocking ferroptosis protects nerve cells during a stroke, reduces kidney injury, and could even help in diseases such as Alzheimer’s and Parkinson’s. More recently, scientists saw that blocking ferroptosis may help cancer treatments work better. Tumors have a sneaky way of surviving stress that usually would kill other cells, and figuring out how to remove that shield could give doctors an edge.
Today, much of the hype around Ferrostatin-1 boils down to its usefulness as a research tool. You won’t find this compound in pharmacies. It hasn’t passed safety hurdles for people. What it does do is help scientists pinpoint which diseases involve ferroptosis and how to block or tweak it. Real progress hinges on understanding pathways inside our bodies, down to which tiny molecules pull the strings.
Many research teams—including those funded by the National Institutes of Health, top universities, and biotech start-ups—follow data trails left by Ferrostatin-1. In animal studies, this molecule reduced damage after strokes, slowed nerve loss in ALS models, and even shielded transplanted kidneys in rodents from iron-driven breakdown.
Peer-reviewed studies over the past decade back up these claims. For example, “Nature Chemical Biology” published work showing that inhibiting ferroptosis could protect mouse brains when cut off from oxygen. Another report from “Nature” linked lipid imbalance to both cell death and a rise in degenerative disease symptoms. Seeing these parts fit together pushed more scientists to test combinations: blocking ferroptosis alongside traditional treatments or using ferroptosis as a new angle in cancer therapy.
Anybody who has followed the jump from laboratory promise to clinical reality knows bumps along the road are common. From my perspective, sharing hope is important, but setting expectations matters just as much. Side effects, unexpected toxicities, and difficulties in delivering such compounds to the right tissues stand as real obstacles. Creating safe drugs for people means modifying, testing, and understanding molecules like Ferrostatin-1 over years, not months.
Collaboration fuels progress. More open research and smart public funding could speed up the transition from cell culture to patient care. Supporting talented young researchers diving deep into these pathways holds the potential to rewrite how we address everything from traumatic injury to age-linked disease. As curiosity drives further discoveries, tools like Ferrostatin-1 remind us that science moves forward one carefully measured step at a time.
Most of my work and research have circled around how cells survive stress, aging, and injury. Lately, one of the most intriguing stories in science rests in a type of cell death called ferroptosis. Unlike the usual suspects—apoptosis or necrosis—ferroptosis gets triggered by iron and an overload of damaging molecules known as lipid peroxides. If that sounds technical, break it down this way: iron, often hailed for carrying our oxygen and giving blood its red color, sometimes flips its friendly face. In too high concentrations, it sparks uncontrollable chemical fires in cells, burning them from the inside out.
I remember reading the 2012 paper that first mentioned Ferrostatin-1 in detail. Researchers tested dozens of chemicals, searching for something to stop this iron-driven chaos. Out of that testing marathon, Ferrostatin-1 stood out. This compound acts almost like a firefighter—it targets and smothers those destructive fires in cell membranes. When more iron causes fatty components of membranes to break apart, Ferrostatin-1 sweeps in to intercept the chain reactions, keeping cell walls intact.
It’s not complicated, but it’s clever. Ferrostatin-1 latches onto lipid radicals before they run amok. These radicals, left unchecked, punch holes in cells and eventually kill them. By stepping in at this critical moment, Ferrostatin-1 blocks this progression. In studies using nerve cells, the molecule shielded them from death, even under intense stress that should have finished them off. This reaction doesn’t depend on changing genes or switching off iron flow; it works right at the scene of the crime—the site where peroxidation begins.
Every week, someone asks about the slow creep of neurodegenerative disease or the misery of acute kidney injury. These problems don’t just pop up out of nowhere; iron and oxidative stress drive a lot of them. For families dealing with conditions like Alzheimer’s or stroke, every protective molecule brings a flicker of hope. Ferrostatin-1 is still experimental, but in animal tests, it slowed down tissue destruction by interrupting cell death at its earliest stage.
The bigger story here isn’t just a chemical trick. By blocking ferroptosis, scientists peel back another layer on the puzzle of why diseases get worse so suddenly. Too often, therapies chase symptoms after the damage piles up. Ferrostatin-1 points to a future where we can freeze the chain reaction before it starts eating away at vital cells.
Nothing in medicine shifts overnight. Chemicals like Ferrostatin-1 go through years of testing before reaching a doctor’s prescription pad. One challenge comes from turning a discovery in a dish into something safe for people. Ferrostatin-1 works well in cells and animal tissues, but the body’s chemistry can transform or weaken molecules. Researchers need to tweak its structure to stand up against metabolism and reach target tissues.
Long-term, the best use probably comes from combining this with other medicines. Stopping ferroptosis may buy time and save tissue, but chronic diseases bring their own mix of troubles. Trials need to look at how Ferrostatin-1 interacts with common treatments and what it means for people already on complicated drug regimens.
Getting from the lab to clinic always takes grit, funding, and relentless trial and error. The early results give hope to anyone watching a loved one fade from brain injury or chronic inflammation. If anything, the lesson from Ferrostatin-1 isn’t just about chemistry; it’s about the relentless drive to understand and intervene in the processes that quietly erode health.
Researchers working with Ferrostatin-1 recognize the compound’s role in studying ferroptosis, an entirely different type of programmed cell death compared to apoptosis. Studies on neurodegeneration, cancer, and oxidative injury keep pushing forward, often resting on data generated with Ferrostatin-1. If storage mishaps hit, experiment results wobble and can mislead whole projects. My own time working on small molecule inhibitors showed me just how sensitive some research tools can be. Tiny lapses—a lab fridge left open for an afternoon—sometimes spelled weeks of wasted effort.
Ferrostatin-1 does not like moisture or high temperatures. Suppliers, such as Sigma-Aldrich and Cayman Chemical, all recommend storing it dry and cold. The gold standard: keep it tightly capped at -20°C. Moisture reacts with the molecule’s sensitive groups, tanking both purity and activity. Light also risks speeding up degradation, so amber vials work better than clear ones. Taking note of these precautions lines up with decades of chemical storage wisdom shared by both manufacturers and trusted academic sources.
Lab fridges often get crowded, so a special section for sensitive reagents helps. In one well-run chemistry group I advised, the shelves marked “dedicated dry storage” beat the temptation to store everything anywhere. Each bottle stayed in a sealed bag with desiccant packs and backup labels. We tracked every freeze-thaw to avoid unnecessary cycles, since repeated warming and chilling can stress molecules like Ferrostatin-1. More than one major experiment fell apart in groups where nobody respected the instructions.
Deep freezing slows down chemical breakdown. At -20°C, the molecular machinery that destroys small inhibitors slows almost to a halt. Some labs skip proper freezers and just use the fridge, not realizing the difference in long-term stability. A molecule like Ferrostatin-1 may survive a week or two at 4°C, but break down over months. Enough breakdown and you might not even notice by eye, yet get a subtle drop in potent activity. This detour wastes time and budget, and leads to bad data.
A dry, sealed tube beats condensation every time. Ferrostatin-1 crystals or powder need as little air and light as possible, especially once you break open the original packaging. If you dissolve the molecule in a solvent like DMSO, return unused stock to the freezer immediately after aliquoting. Many labs slip up at this step, leaving stock solutions at room temperature during a long experiment, letting hours roll by before returning them to cold storage. Over a year, these small mistakes add up to lots of wasted compound and faulty results.
Labeled, organized freezer space. Lab-wide SOPs for handling. Routine checks on the condition and temperature of freezers. All these seem basic until a major project gets derailed by a bad bottle. I’ve seen groups pin down the problem only after running expensive analytical checks, wishing they’d stuck with caution from the beginning. Good storage keeps research honest, waste low, and findings reliable.
Ferrostatin-1 caught the attention of scientists with its ability to stop cells from dying due to iron-driven oxidation, the sort you see in many diseases. You spot its name mostly in research papers or biotech presentations, not on prescriptions. No surprise there. A quick look through headlines or clinical trial databases shows Ferrostatin-1 isn’t approved for doctors to give to people. Universities and biotech firms treat it as a research compound, not as a medicine you pick up at the pharmacy.
Every year some new molecule makes waves in early experiments, and hope flies around—but most of those fade away once the real-world testing begins. Ferrostatin-1 shows promise in lab models for brain injuries, kidney damage, and neurodegeneration. None of that guarantees relief for real people yet. Labs use it to answer questions about how cells die, to build up data before anything happens in clinics.
Developing a drug takes years and a mountain of evidence. Take cancer drugs or treatments for rare diseases as examples—scientists test, re-test, and make sure the risks don’t outweigh the benefits. With Ferrostatin-1, there’s no data from studies in people. Animal work tells us about potential, but humans are complicated. Side effects could show up that never happened in mice or cells on a dish. I’ve seen stories where a molecule looked perfect in the petri dish but failed in the body because of metabolism or unexpected toxic reactions. That’s part of the reason researchers move slowly and want every bit of safety data possible before trying anything in a patient.
Trust in new medical solutions builds on solid science and transparency. Regulatory agencies like the FDA and EMA dig deep, reading every report before something earns approval. They look at manufacturing standards and how reliable lab results turn out over and over. If there's no announcement of phase one or two clinical trials, it’s a pretty clear sign: Ferrostatin-1 hasn’t reached the stage where people outside of controlled research facilities can safely use it.
People dealing with painful or fatal diseases look for hope in any scientific news. Seeing a headline mentioning Ferrostatin-1’s breakthrough in mice carries emotional weight. The frustration when real treatment remains years away is real—I’ve heard it in conversations with patients holding onto early lab results about new compounds. Real hope means real data. Shortcuts in drug development have cost lives before, so patience isn’t just bureaucracy; it’s safety.
Researchers can be more upfront about where compounds like Ferrostatin-1 actually stand. Science news should set honest expectations, not get ahead of the facts. Open databases, clear updates about clinical progress, and sharing setbacks as clearly as successes help cut through hype. Investors and patients both deserve honest timelines and risks spelled out in plain language.
Ferrostatin-1 doesn’t sit in the medicine cabinet yet. If you read about its potential, remember it’s still in the hands of research teams. Stories change only after trials prove both safety and benefit for people, not just animals or cells. Until then, using it remains a tool for scientific discovery, not for treating patients.
Sometimes, hunting for the real story behind a molecule makes me feel like I’m back in high school chemistry, only now the stakes are much higher. Ferrostatin-1, or Fer-1 as researchers like to call it, packs a punch when it comes to stopping a certain kind of cell death called ferroptosis. But none of that matters if you don’t know what makes up this molecule. The chemical structure hangs on a backbone of an aromatic amine, pointing to a benzene ring with some strategic substitutions. Imagine attaching a 4-(benzylamino) group to a 2-(4-methoxyphenyl)-2-oxoethyl structure, forging a skeleton that’s both rigid and versatile. The full IUPAC name, for anyone bold enough to keep reading chemistry papers, is quite a mouthful: 3-(benzyloxy)-N-[4-(1,3,2-dioxazol-4-yl)phenyl]-4-methoxybenzenecarboxamide.
All those rings and side groups might seem nerdy, but they actually matter. The way those atoms sit—where the benzene rings flank the core, how the methoxy group plugs into the scene—lets Ferrostatin-1 slip into the cell membrane and shield cells from damage that comes when iron and lipids start to tango too hard.
Many scientists (and the rest of us, really) trust numbers more than anything. Ferrostatin-1 weighs in with a molecular mass of MW 315.39 g/mol. It’s not the heaviest compound on the shelf, but it’s got enough heft to squeeze into science experiments without hogging all the bandwidth. This weight means a researcher can easily dissolve it and give cells just the right dose, which matters when you care about accuracy and not wasting precious lab budgets.
Knowing the skeleton of Ferrostatin-1 isn’t a party trick—it matters for clear reasons. Drug development lives and breathes on molecules with unique structures that do one thing without causing chaos everywhere else. If you’ve ever watched family or friends manage a disease that barely budges with older drugs, you know new targets bring hope. Ferrostatin-1’s design lets it block cell death in a way some researchers think could slow down neurological diseases or catastrophic injuries—places where plain old antioxidants just don’t cut it.
When scientists tinker with this molecule, they check every twist and turn of those rings. Changing a methyl group or swapping an oxygen atom can snuff out the molecule’s power or send it to the wrong part of the cell. Chemical structure isn’t just trivia; it acts as a road map for anyone aiming to make something even better, or catch side effects before clinical trials chew up years and dollars.
Markets, patients, and doctors don’t wait for the next big thing forever. Reliability and transparency in chemical details—like the exact structure and molecular weight—keep everyone honest. It builds trust and lets investors see through the hype. It also gives regulators confidence that a new therapy won’t go off-target or react badly with other treatments.
Whenever I hear about hope for new therapeutics, I check if the foundational information—like the chemical structure and molecular weight—is public, verified, and consistent across journals. That habit grew from watching treatments promising miracles, only to vanish when the basics didn’t add up. Ferrostatin-1 might only weigh about 315 grams per mole, but clear facts keep the science from sinking, especially when lives hang in the balance.
| Names | |
| Preferred IUPAC name | 3-(2-(4-(morpholin-4-yl)phenoxy)acetyl)-2-phenyl-1H-indole |
| Other names |
Fer-1 ferroptosis inhibitor 1 |
| Pronunciation | /ˌfɛr.oʊˈstæt.ɪn wʌn/ |
| Identifiers | |
| CAS Number | 347174-05-4 |
| Beilstein Reference | 11050647 |
| ChEBI | CHEBI:90941 |
| ChEMBL | CHEMBL3133807 |
| ChemSpider | 21589335 |
| DrugBank | DB13970 |
| ECHA InfoCard | 100.248.942 |
| EC Number | 347174-05-4 |
| Gmelin Reference | 1620614 |
| KEGG | C17095 |
| MeSH | D000072600 |
| PubChem CID | 50909430 |
| RTECS number | VO1986000 |
| UNII | DS5B9433V9 |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID10888764 |
| Properties | |
| Chemical formula | C21H22N2O2 |
| Molar mass | 286.34 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.36 g/cm³ |
| Solubility in water | Insoluble |
| log P | 2.6 |
| Acidity (pKa) | 10.53 |
| Basicity (pKb) | 14.09 |
| Refractive index (nD) | 1.661 |
| Viscosity | Viscous oil |
| Dipole moment | 4.83 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 220.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of Ferrostatin-1: "-8022 kJ/mol |
| Pharmacology | |
| ATC code | V03AX31 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | C1=CC(=CC=C1C(C2=CC=CC=C2)N3CCCC3=O)O |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Precautionary statements: "Wash skin thoroughly after handling. Wear protective gloves/eye protection/face protection. |
| Flash point | > 184.6 °C |
| LD50 (median dose) | LD50 (median dose): >100 mg/kg (Mouse, intraperitoneal) |
| NIOSH | |
| REL (Recommended) | 2-5 µM |
| Related compounds | |
| Related compounds |
Liproxstatin-1 Necrostatin-1 Necrosulfonamide Deferoxamine Vitamin E |
